Akcea, A Wholly Owned Subsidiary Of Ionis Pharmaceutical, Set To IPO

Conclusion: Consider A Modest Investment

Akcea products have generated significant interest, and a strategic partnership with Novartis bodes well for its continued growth and development.

Additionally, the fact that company insiders are planning to purchase $25M worth of shares at the IPO shows their confidence and belief in its future success.

Despite the high risk associated with investing in early stage biopharma, we feel Akcea is a good pick for aggressive investors comfortable with risk and looking for exposure to the industry.

1 2 3
View single page >> |

Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in AKCA over the next 72 hours.

Disclaimer: I wrote this article myself, and it ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.